

1 **Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral**
2 **Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2**

3 Wendy P. Painter,^{1#} Wayne Holman,¹ Jim A. Bush,² Firas Almazedi,² Hamzah Malik,² Nicola C.
4 J. E. Eraut,² Merribeth J. Morin,¹ Laura J. Szewczyk,¹ George R. Painter³

5 1. Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United
6 States.

7 2. Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH,
8 United Kingdom.

9 3. Department of Pharmacology and Chemical Biology, Emory University School of Medicine,
10 954 Gatewood Road NE, Atlanta, Georgia 30329, United States.

11 # corresponding author

12 **Running title:** Safety and Pharmacokinetics of Molnupiravir

13 **Abstract**

14 Molnupiravir, EIDD-2801/MK-4482, the prodrug of the ribonucleoside analog
15 β -d-N4-hydroxycytidine (NHC), has activity against a number of RNA viruses including severe
16 acute respiratory syndrome coronavirus 2, severe acute respiratory syndrome coronavirus,
17 Middle East respiratory syndrome coronavirus, seasonal and pandemic influenza viruses, and
18 respiratory syncytial virus.

19 Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1,
20 randomized, double-blind, placebo-controlled study in healthy volunteers, which included
21 evaluation of the effect of food on pharmacokinetics.

22 EIDD-1931 appeared rapidly in plasma, with a median time of maximum observed concentration
23 of 1.00 to 1.75 hours, and declined with a geometric half-life of approximately 1 hour, with a
24 slower elimination phase apparent following multiple doses or higher single doses (7.1 hours at
25 the highest dose tested). Mean maximum observed concentration and area under the
26 concentration versus time curve increased in a dose-proportional manner, and there was no
27 accumulation following multiple doses. When administered in a fed state, there was a decrease in
28 the rate of absorption, but no decrease in overall exposure.

29 Molnupiravir was well tolerated. Fewer than half of subjects reported an adverse event, the
30 incidence of adverse events was higher following administration of placebo, and 93.3% of
31 adverse events were mild. One discontinued early due to rash. There were no serious adverse
32 events and there were no clinically significant findings in clinical laboratory, vital signs, or
33 electrocardiography. Plasma exposures exceeded expected efficacious doses based on scaling
34 from animal models; therefore, dose escalations were discontinued before a maximum tolerated
35 dose was reached.

36 **Clinical trial identifier:** This study was registered at ClinicalTrials.gov with the identifier
37 NCT04392219.

38 **Introduction**

39 A novel coronavirus, originally identified in Wuhan City, China, was reported to the World
40 Health Organization on 31 December 2019 (1) and the associated disease has subsequently
41 become a worldwide pandemic. An effective antiviral therapeutic has since been intensively
42 sought.

43 The causative agent of the current pandemic, severe acute respiratory syndrome coronavirus 2
44 (SARS-CoV-2), is a sister clade to severe acute respiratory syndrome coronavirus (SARS-CoV),
45 the causative agent of severe acute respiratory syndrome (SARS). SARS emerged in Guangdong,
46 China in 2002, causing over 700 deaths among over 8000 cases. The severity of this epidemic in
47 2002-2003 was limited by the relatively low transmissibility of SARS-CoV and association of
48 peak viremia with clinical symptoms rather than a prodromal phase (2); however, the epidemic
49 demonstrated the potential for the rapid spread of an infectious disease in a highly connected and
50 interdependent world. This risk was emphasized when another novel coronavirus, the Middle
51 East respiratory syndrome coronavirus (MERS-CoV), the causative agent of Middle East
52 respiratory syndrome (MERS), emerged in 2012 and resulted in a localized epidemic in 2014.

53 SARS-CoV-2 has now established itself globally in the human population. Thus, there is an
54 urgent need for an effective, oral antiviral that can be manufactured and broadly distributed on a
55 scale adequate to meet global need. Such a therapy could prevent deaths, reduce disease severity,
56 reduce hospital admission times and thus lessen stress on healthcare resources, potentially limit
57 the spread of SARS-CoV-2, and ameliorate the global and economic disruption that was initiated
58 by the Coronavirus disease-2019 (COVID-19) pandemic.

59 COVID-19 may be asymptomatic, mild, severe, life-threatening, or fatal. While the majority of
60 cases can be managed in an outpatient setting, patients with risk factors including advanced age,
61 cardiovascular and pulmonary comorbidities, diabetes, obesity, chronic kidney disease, and
62 cancer are at higher risk of developing more severe disease that may require hospitalization or
63 may result in death and severe morbidity. Asymptomatic carriers and those with mild disease
64 may spread the disease to those at high risk and may subsequently suffer less common and
65 emerging medium-to-longer term sequelae, such as multi-system inflammatory syndrome in
66 children or prolonged cardiopulmonary compromise in otherwise healthy adults (3). Healthcare
67 utilization stresses in regions with outbreaks, quarantines, school closures, and isolation of the
68 elderly may create further disruption and morbidity because of effects on the normal running of
69 hospital services, including cancer referrals and management of chronic conditions. The overall
70 fatality rate is likely higher than for influenza, but estimates are still changing based on emerging
71 data (4). As with other viral respiratory diseases, fatalities are heavily skewed toward older
72 patients and those with risk factors; children are rarely symptomatic and rarely have serious
73 illness.

74 COVID-19 is primarily a respiratory disease, but many extrapulmonary effects and
75 complications have been described. Cough and fever are the most frequent symptoms, followed
76 by myalgia, headache, dyspnea, sore throat, diarrhea, nausea/vomiting, and anosmia or ageusia
77 (5). These initial COVID-19 symptoms are not easily distinguished from other respiratory
78 infections such as influenza; therefore, a broad-spectrum treatment would be advantageous for
79 empiric therapy. Complications of COVID-19 include respiratory failure, cardiovascular events,
80 thromboembolic events, and inflammatory damage (6), and respiratory sequelae are anticipated
81 in patients with severe disease (7). Thus, administration of a potent, direct-acting antiviral at

82 various stages of viral replication may reduce not only acute disease symptoms and transmission,
83 but also complications and sequelae of untreated progressive disease.

84 Molnupiravir (also known as EIDD-2801/MK-4482) is a prodrug of the ribonucleoside analog
85 β -d-N4-hydroxycytidine (EIDD-1931 [NHC]), which is phosphorylated intracellularly to the
86 active 5'-triphosphate. Molnupiravir has demonstrated the potential to treat infections caused by
87 several RNA viruses, including pandemic-capable coronaviruses and influenza viruses, and
88 encephalitic alpha viruses such as Venezuelan, Eastern, and Western equine encephalitis viruses
89 in nonclinical models. The primary mechanism of action of molnupiravir against RNA viruses is
90 viral error catastrophe (8, 9), a concept that is predicated on increasing the viral mutation rate
91 beyond a biologically tolerable threshold, resulting in impairment of viral fitness and leading to
92 viral extinction. Molnupiravir has demonstrated *in vitro* activity against SARS-CoV-2 in human
93 airway epithelial cell cultures. Prophylactic and therapeutic administration of molnupiravir to
94 mice infected with SARS-CoV or MERS-CoV improved pulmonary function, and reduced virus
95 titer and body weight loss (10). In the ferret influenza model, treatment of pandemic influenza A
96 virus with molnupiravir resulted in reduced viral shedding and inflammatory cellular infiltrates
97 in nasal lavages, with a normal humoral antiviral response (11).

98 Here we report the results of a first-in-human, phase 1, randomized, double-blind, placebo-
99 controlled study to determine the safety, tolerability, and pharmacokinetics of single and multiple
100 ascending oral doses of molnupiravir in healthy subjects. A randomized, open-label, crossover
101 evaluation in the fed (high fat) and fasted states was also conducted to assess the effect of food
102 on the pharmacokinetics of single doses of molnupiravir.

103 **Results**

104 Eligible subjects were randomized in a 3:1 ratio to either study drug or placebo in the single- and
105 multiple-ascending-dose parts of the study. Each cohort comprised 8 subjects, with single oral
106 doses of 50 to 1600 mg administered in the single-ascending-dose part and twice-daily (BID)
107 doses of 50 to 800 mg administered for 5.5 days in the multiple-ascending-dose part. Subjects
108 were followed for 14 days following completion of dosing for assessments of safety, tolerability,
109 and pharmacokinetics. Subjects in the food-effect evaluation were randomized in a 1:1 ratio to
110 either 200 mg molnupiravir in the fed state followed by 200 mg molnupiravir in the fasted state,
111 or vice versa, with a 14-day washout period between doses. A capsule formulation was used in
112 all parts of the study, with the exception of single ascending doses ≤ 800 mg, where an oral
113 solution formulation was used.

114 **Disposition.** Sixty-four subjects received a single dose of between 50 and 1600 mg molnupiravir
115 or placebo; 55 subjects received between 50 and 800 mg molnupiravir or placebo BID for 5.5
116 days; and 10 subjects received a single dose of 200 mg molnupiravir in the fed state followed by
117 a single dose of 200 mg molnupiravir in the fasted state after a washout period of 14 days, or
118 vice versa. Additionally, 1 subject in the multiple-ascending-dose part received 800 mg
119 molnupiravir BID for 3 days, but was discontinued from dosing by the investigator on Day 4. All
120 subjects completed the protocol-specified study procedures and assessments.

121 **Demography.** Subjects were aged between 19 and 60 years, with a mean body mass index
122 between 24.4 and 25.4 kg/m² (Table 1). The majority of subjects were white and male. There
123 were no other notable differences in subject demography between cohorts, except for age, where

124 the mean age was higher in the food-effect evaluation cohort, the 50-mg molnupiravir single-
125 dose cohort, and in the 100-mg molnupiravir multiple-dose cohort (data not shown).

126 **Tolerability.** Adverse events were graded using the Division of Microbiology and Infectious
127 Diseases (DMID) toxicity grading, dated March 2014. **(i) Single ascending doses.** Overall,
128 37.5% of subjects reported an adverse event (Table 2). There were no apparent dose-related
129 trends, with a greater proportion of subjects reporting adverse events following administration of
130 placebo (43.8%) than following administration of molnupiravir (35.4%). Only 1 moderate
131 adverse event (headache; Grade 2) was reported following administration of molnupiravir, which
132 occurred at the 400-mg dose level. One subject also reported moderate adverse events (nausea
133 and headache; Grade 2) following administration of placebo. No severe (Grade 3) adverse events
134 were reported. The most frequently reported adverse event was headache, which was reported by
135 18.8% of subjects who were administered placebo and 12.5% of subjects who were administered
136 molnupiravir. **(ii) Multiple ascending doses.** Overall, 44.6% of subjects reported an adverse
137 event (Table 3). There were no apparent dose-related trends, with a greater proportion of subjects
138 reporting adverse events following administration of placebo (50.0%) than following
139 administration of molnupiravir (42.9%). With the exception of 1 subject who reported moderate
140 (Grade 2) events of oropharyngeal pain, pain in extremity, and influenza-like illness, all adverse
141 events were mild (Grade 1) in severity. The most frequently reported adverse event was diarrhea,
142 which was reported by 7.1% of subjects who were administered molnupiravir and 7.1% of
143 subjects who were administered placebo. One subject discontinued study drug administration on
144 Day 4 because of an adverse event of mild, truncal, maculopapular, pruritic rash following
145 multiple BID doses of 800 mg molnupiravir, which was considered by the investigator to be
146 related to the study drug. Following discontinuation, the subject was administered potent topical

147 steroid treatment and anti-histamines, and pruritis and rash had both resolved within 18 days. (iii)

148 **Food-effect evaluation.** Three subjects in the food-effect evaluation each reported 1 adverse
149 event, all of which were mild (Grade 1) in severity.

150 There were no serious adverse events reported in this study and there were no trends of increased
151 frequency or severity of adverse events with higher doses of molnupiravir.

152 **Safety.** There were no clinically significant findings or dose-related trends in clinical laboratory,
153 vital signs, and electrocardiogram data. The dose-limiting toxicity in one Investigational New
154 Drug-enabling study (in the dog, the most sensitive species) was bone marrow toxicity and
155 included reversible reductions in platelet counts; however, no clinically significant changes in
156 hematological parameters were seen in this study.

157 Dose escalations were discontinued before a maximum tolerated dose was reached because
158 plasma exposures that were expected to be efficacious based on scaling from animal models of
159 seasonal and pandemic influenza were exceeded (11).

160 **Pharmacokinetics. (i) Single ascending doses.** Concentrations of molnupiravir were generally
161 not quantifiable at doses up to 800 mg, with the exception of the 0.25-hour timepoint after doses
162 of 600 and 800 mg, where concentrations were quantifiable in 5 and 4 subjects, respectively, and
163 the 0.5-hour timepoint after a dose of 800 mg, where concentrations were quantifiable in all
164 subjects. At doses of 1200 and 1600 mg, concentrations of molnupiravir were quantifiable at 1 or
165 more timepoints between 0.25 and 1.5 hours postdose in all subjects. Molnupiravir
166 pharmacokinetic parameters were not calculable for doses ≤ 400 mg; however, at doses ≥ 600 mg,
167 maximum observed concentration (C_{max}), time of C_{max} (t_{max}), and time of last quantifiable
168 concentration were calculable. Following administration of between 600 and 1600 mg

169 molnupiravir, values of mean C_{\max} were up to 13.2 ng/mL and values of median t_{\max} were
170 between 0.25 and 0.75 hours (data not shown). It should be noted that molnupiravir
171 concentrations represented only approximately 0.2% of EIDD-1931 concentrations and t_{\max} of
172 molnupiravir occurred at the first sampling timepoint for the 600-mg dose level, and therefore
173 C_{\max} may have been underestimated. At doses of ≥ 800 mg, trace amounts of molnupiravir were
174 detected in the urine, which represented approximately 0.002% of the dose (data not shown).

175 Following oral administration of molnupiravir at doses up to 800 mg, EIDD-1931 appeared
176 rapidly in plasma, with a median t_{\max} of 1.00 hour postdose in all dose cohorts, after which
177 plasma concentrations declined in an essentially monophasic manner with geometric mean
178 terminal elimination half-lives ($t_{1/2}$) of between 0.910 and 1.29 hours postdose (Table 4 and
179 Figure 1). However, at doses of 1200 and 1600 mg, median t_{\max} was delayed, with median t_{\max}
180 occurring at 1.75 and 1.50 hours, respectively. Plasma concentrations at doses of 1200 and
181 1600 mg were quantifiable, along with a second slower elimination phase, where mean $t_{1/2}$ was
182 longer with values of 1.81 and 4.59 hours, respectively.

183 The plasma concentration-time profiles were generally well defined, with the percentage of area
184 under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC_{inf}) that was
185 extrapolated being $<10\%$ for all subjects. When assessed using a power model ($\ln[\text{parameter}] =$
186 $\text{intercept} + \text{slope} \times \ln[\text{dose}] + \text{random error}$), mean C_{\max} increased in a dose-proportional manner,
187 with the 90% confidence interval containing unity. Similarly, mean AUC_{inf} increased in an
188 approximately dose-proportional manner; however, the lower bound of the 90% confidence
189 interval was slightly above unity (Table 5).

190 The amount of EIDD-1931 excreted in urine from time 0 to 24 hours postdose (A_{e0-24}) increased
191 supraproportionally with dose, and there was a similar trend for apparent clearance (CL_R) to
192 increase. Between 0.820% (at the 50-mg dose level) and 6.70% (at the 1600-mg dose level) of
193 the dose was excreted in urine as EIDD-1931, and the majority of the total amount was generally
194 excreted within the first 4 hours postdose.

195 **(ii) Multiple ascending doses.** Concentrations of molnupiravir were generally not quantifiable at
196 doses ≤ 400 mg BID and pharmacokinetic parameters were not calculable. Concentrations of
197 molnupiravir were quantifiable in 4 subjects at either 0.5 or 1 hour postdose on Day 1 and in 3
198 subjects at 0.5 hours postdose on Day 6 at the 600-mg BID dose level. At the 800-mg dose level,
199 concentrations of molnupiravir were quantifiable from all except 1 subject at 0.5 hours postdose
200 on Days 1 and 6, but at no other timepoints, consistent with single ascending doses.

201 Following oral administration of molnupiravir, EIDD-1931 appeared rapidly in plasma, with a
202 median t_{max} in all dose cohorts of between 1.00 and 1.75 hours postdose across both Days 1 and
203 6 (Table 6 and Figure 2). For all dose levels, plasma concentrations declined in an essentially
204 monophasic manner on Day 1, with mean $t_{1/2}$ ranging from 0.918 to 1.18 hours. Similarly,
205 plasma concentrations declined in an essentially monophasic manner on Day 6 for subjects at
206 dose levels ≤ 200 mg BID and for the majority of subjects at the 300- and 400-mg BID dose
207 levels. Contrastingly, for 1 subject at each of the 300- and 400-mg dose levels and for all
208 subjects at the 600- and 800-mg BID dose levels, there was the emergence of a second, slower
209 elimination phase on Day 6, which was reflected in an increase in the mean $t_{1/2}$ with increasing
210 dose at doses ≥ 200 mg. Of note, at the 600-mg BID dose level, the lack of a clearly defined
211 terminal elimination phase confounded the evaluation of $t_{1/2}$ for the majority of subjects. At the
212 800-mg BID dose level, the mean $t_{1/2}$ was 7.08 hours.

213 There was no evidence of accumulation, with the geometric mean accumulation ratios based on
214 area under the plasma concentration-time curve during a dosing interval (AUC_{τ}) and C_{\max}
215 between 0.938 and 1.16, and between 0.843 and 1.10, respectively, across all dose levels.

216 On Day 1, when assessed using the power model, mean C_{\max} and AUC_{inf} increased in an
217 approximately dose-proportional manner. However, the upper bound of the 90% confidence
218 interval for C_{\max} was slightly below unity and the lower bound of the 90% confidence interval
219 for AUC_{inf} was slightly above unity (Table 7). On Day 6, mean C_{\max} increased in a dose-
220 proportional manner, with the 90% confidence interval containing unity. Similarly, mean AUC_{τ}
221 increased in an approximately dose-proportional manner; however, the lower bound of the 90%
222 confidence interval was slightly above unity (Table 7).

223 AUC_{inf} on Day 1 for the multiple-dose cohorts, where a capsule formulation was administered,
224 was similar to those for the corresponding single-dose cohorts where a solution formulation was
225 administered, with geometric mean ratios of between 0.91 and 1.09. Geometric mean C_{\max} was
226 slightly lower following dosing with the capsule formulation, with geometric mean ratios of
227 between 0.76 and 1.00, and a trend to smaller ratios at higher doses. Median t_{\max} occurred up to
228 0.75 hours later following administration of the capsule formulation, with the difference being
229 greatest at doses ≥ 600 mg BID. Thus, it appears that the extent of absorption is similar for the
230 solution and capsule formulations, but the rate of absorption appears to be slightly slower for the
231 capsules. However, these data should be interpreted with caution because this was not a
232 crossover study.

233 Between 0.854% and 3.61% of the dose was excreted in urine as EIDD-1931 on both Days 1 and
234 6, and, similar to single doses, the majority was excreted in the first 4 hours postdose (Table 6).

235 There was no consistent dose-related trend in the percentage of dose administered recovered in
236 urine during a dosing interval ($Fe_{0-\tau}$) or CL_R at doses ≤ 200 mg BID. However, there was a trend
237 for $Fe_{0-\tau}$ and CL_R to increase with dose at doses > 200 mg BID, with a 4-fold increase in dose
238 from 200 to 800 mg BID resulting in a 16-fold increase in the amount of the dose recovered in
239 urine during a dosing interval ($Ae_{0-\tau}$) on Day 1 and an 11-fold increase in $Ae_{0-\tau}$ on Day 6.

240 **(iii) Food effect.** Concentrations of molnupiravir were generally not quantifiable and
241 pharmacokinetic parameters were not calculable. Concentrations of EIDD-1931 were
242 quantifiable at 0.25 hours postdose for 2 subjects in the fasted state, but no subjects in the fed
243 state. The first quantifiable concentrations in the fed state were between 0.5 and 1.5 hours
244 postdose.

245 Following administration of 200 mg molnupiravir in the fed state, t_{max} of EIDD-1931 occurred
246 later, with a median of 3.00 hours postdose versus 1.00 hour postdose (Table 8 and Figure 3).
247 Generally, the slower absorption and later t_{max} in the fed state was reflected in lower C_{max} ;
248 however, 1 subject had similar profiles for both treatments (data not shown). Mean C_{max} was
249 approximately 36% lower in the fed state compared to the fasted state, but exposure (assessed by
250 AUC_{inf}) was similar for both fed and fasted states and demonstrated that the extent of absorption
251 was similar. Following C_{max} , concentrations of EIDD-1931 declined in an essentially
252 monophasic manner in both the fed and fasted state and remained quantifiable until between 9
253 and 15 hours postdose in the fed state and between 6 and 9 hours in the fasted state. The mean
254 $t_{1/2}$ was similar between fed and fasted treatments, with values of 1.09 and 0.977 hours,
255 respectively. Urine pharmacokinetic parameters were similar to those reported for single
256 ascending doses.

257 **Discussion**

258 There is a significant need for an antiviral drug against coronaviruses with pandemic potential
259 that is generally safe and well tolerated and can be easily administered in the outpatient setting.

260 The oral route of administration of molnupiravir makes it appropriate and convenient for
261 administration to outpatients.

262 Additionally, if further studies demonstrate that molnupiravir has an acceptable risk/benefit
263 profile, its oral route of administration may allow for evaluation in a prophylactic setting. Among
264 350 cases of COVID-19 in the United States where exposures were solicited, approximately half
265 of respondents reported a known exposure in the 2 weeks prior to the illness, with 45% exposed
266 from an infected family member and 34% exposed from an infected work colleague (12). This
267 suggests a need for treatment of infected individuals and their close contacts in an outpatient
268 setting to reduce viral shedding and infectivity, thereby reducing transmission.

269 Furthermore, SARS-CoV-2 RNA has been found in multiple organs at autopsy, indicating the
270 ability to spread systemically (13). Molnupiravir is converted in plasma to EIDD-1931, which is
271 subsequently well distributed to tissues including lung, spleen, and brain (9); therefore, it can
272 localize to sites of replication in the treatment of systemic disease. An antiviral drug, such as
273 molnupiravir, with broad distribution once absorbed is a desirable attribute for an emerging
274 therapy for the treatment of COVID-19.

275 Plasma exposures expected to be efficacious, based on scaling from animal models of seasonal
276 and pandemic influenza, were exceeded(11). Molnupiravir, having demonstrated good
277 tolerability and dose-proportional pharmacokinetics with relatively low variability following

278 administration to healthy volunteers at clinically relevant doses is well positioned to be evaluated
279 for clinical efficacy and safety in large-scale COVID-19 studies.

280 **Materials and Methods**

281 **Study population.** Healthy subjects, of any ethnic origin, race, or sex, aged between 18 and 60
282 years, inclusive, and with a body mass index between 18 and 30 kg/m², inclusive, were eligible
283 to participate in this study. Potential subjects were screened for inclusion in the study within 28
284 days prior to the first dose administration after voluntarily providing informed consent.

285 **Study design.** Eligible subjects were randomized in a 3:1 ratio to either study drug or placebo in
286 the single- and multiple-ascending-dose parts. Placebo was chosen as the control treatment to
287 assess whether any observed safety and tolerability effects were related to the treatment or
288 simply reflected the study conditions. Each dose-escalation cohort comprised 8 subjects, with
289 single oral doses of 50 to 1600 mg administered in the single-ascending-dose part and BID doses
290 of between 50 and 800 mg for 5 days with a final dose on the morning of Day 6 being
291 administered in the multiple-ascending-dose part. Safety and tolerability data up to 72 hours
292 postdose (post final dose for multiple ascending doses) were reviewed prior to each dose
293 escalation to ensure that it was safe to proceed with the planned design and multiple doses were
294 not administered until the planned total daily dose had been shown to be safe and well tolerated
295 as a single dose. Subjects were followed for 14 days following dose administration (post final
296 dose for subjects who received multiple doses) for assessments of safety, tolerability, and
297 pharmacokinetics, which exceeded 5 half-lives of EIDD-1931 observed in nonclinical studies
298 ($t_{1/2}$ = 9.1 hours in dogs and 5 hours in ferrets).

299 Subjects in the food-effect evaluation were randomized in a 1:1 ratio to either 200 mg
300 molnupiravir in the fed state followed by 200 mg molnupiravir in the fasted state, or vice versa.
301 Randomization was performed and subjects were followed as described for the single- and
302 multiple-ascending-dose parts. There was a 14-day washout period between doses in the food-
303 effect evaluation.

304 A capsule formulation was used in all parts of the study, with the exception of single ascending
305 doses \leq 800 mg, where an oral solution formulation was used.

306 The study was conducted in accordance with the International Council for Harmonisation Good
307 Clinical Practice guidelines, the ethical principles outlined in the Declaration of Helsinki, and the
308 European Union Clinical Trial Directive (2001/20/EC) following approval by applicable
309 regulatory authorities and receipt of a favorable opinion by an ethics committee.

310 **Objectives and endpoints.** The primary objectives of this study were: (i) to determine the safety
311 and tolerability of single and multiple ascending doses of molnupiravir, and (ii) to assess the
312 effect of food on the pharmacokinetics of molnupiravir and EIDD-1931 following a single dose.
313 The secondary objective of the study was to define the pharmacokinetics of molnupiravir and
314 EIDD-1931 in plasma and urine following single and multiple doses in healthy subjects. The
315 safety and tolerability endpoints were clinical laboratory evaluations, vital signs,
316 electrocardiograms, physical examinations, and adverse events. Pharmacokinetic endpoints
317 included plasma and urinary parameters.

318 **Criteria for evaluation.** Following single doses, plasma and urine samples for pharmacokinetic
319 analysis were collected up to 72 and 48 hours postdose, respectively. Following multiple doses,
320 plasma and urine samples were collected up to 12 hours after the first dose and up to 192 and

321 72 hours postdose, respectively, after the final dose. Pharmacokinetic samples were analyzed for
322 molnupiravir and EIDD-1931 using a validated liquid chromatography with tandem mass
323 spectrometry bioanalytical method. Pharmacokinetic parameters were calculated using
324 noncompartmental methods in Phoenix WinNonlin Version 8.1.

325 Safety and tolerability were monitored throughout study participation through recording of
326 adverse events, clinical laboratory evaluations, vital signs, electrocardiogram measurements, and
327 physical examinations. Adverse events were monitored by observation of signs and symptoms,
328 open questioning, and spontaneous reporting, and were graded according to the National
329 Institutes of Health Division of Microbiology and Infectious Disease toxicity grading scale.

330 **Sample size and statistical analysis.** No formal sample size calculation was conducted;
331 however, 8 subjects per cohort was considered sufficient for an adequate pharmacokinetic
332 analysis following single and multiple doses. Ten subjects in the food-effect evaluation was
333 typical of food-effect studies with a randomized crossover design. Data were presented using
334 descriptive statistics.

335 **Data availability.** Certain data (for example, subject-level data) will be withheld from disclosure
336 due to national and/or regional regulatory requirements and data protection policies. Other data
337 will be available on request within 6 months of this publication via direct communication with
338 the corresponding author.

339 **Acknowledgements**

340 Ridgeback Biotherapeutics LP funded this study and has subsequently entered into a
341 collaboration with Merck to jointly develop molnupiravir. WP is an employee of Ridgeback

342 Biotherapeutics LP and previously was a consultant to Emory Institute of Drug Development;
343 MM and LS are employees of Ridgeback Biotherapeutics; WH is a co-founder, owner, and
344 advisor to Ridgeback Biotherapeutics; FA, HM, and NE are employees of Covance Clinical
345 Research Unit Limited (the drug development division of Laboratory Corporation of America
346 Holdings), which was responsible for the clinical conduct of this study; JB is an employee of
347 Covance Clinical Research Unit Limited and is an equity holder of Laboratory Corporation of
348 America Holdings; GP is the director of the Emory Institute of Drug Development, is the chief
349 executive officer of Drug Innovation Ventures at Emory, and has a financial interest in
350 molnupiravir.

351 The authors are grateful to the extraordinary collaboration between Ridgeback Biotherapeutics,
352 Covance, the Medicines and Healthcare products Regulatory Agency, and the North East – York
353 Research Ethics Committee that made the study conduct efficient and possible. The authors
354 would also like to acknowledge Dr Mark Stead of Covance Medical Writing for help with the
355 preparation of this manuscript.

356 **References**

- 357 1. World Health Organization. 2020. Novel coronavirus (2019-nCoV) situation report - 1.
- 358 2. Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, Leung GM, Lam
359 TH, Hedley AJ. 2004. Epidemiology, transmission dynamics and control of SARS: the 2002-
360 2003 epidemic. *Philos Trans R Soc B Biol Sci* 359:1091–1105.
- 361 3. Centers for Disease Control and Prevention. 2020. Coronavirus Disease 2019 (COVID-19).
362 *Cent Dis Control Prev*.

- 363 4. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. 2020. The many estimates of
364 the COVID-19 case fatality rate. *Lancet Infect Dis* 20:776–777.
- 365 5. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y,
366 Fullerton KE. 2020. Coronavirus disease 2019 case surveillance — United States, January
367 22–May 30, 2020. *MMWR Morb Mortal Wkly Rep* 69:759–765.
- 368 6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao
369 Y, Li Y, Wang X, Peng Z. 2020. Clinical characteristics of 138 hospitalized patients with
370 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 323:1061–1069.
- 371 7. Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, Zhou X, Liu X, Huang X, Yuan S, Chen
372 C, Gao F, Huang J, Shan H, Liu J. 2020. Impact of coronavirus disease 2019 on pulmonary
373 function in early convalescence phase. *Respir Res* 21:163.
- 374 8. Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, Bluemling GR,
375 Lockwood MA, Sheahan TP, Sims AC, Natchus MG, Saindane M, Kolykhalov AA, Painter
376 GR, Baric RS, Denison MR. 2019. Small-molecule antiviral β -D-N4-hydroxycytidine
377 inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. *J Virol*
378 93:e01348-19.
- 379 9. Painter GR, Bowen RA, Bluemling GR, DeBergh J, Edpuganti V, Gruddanti PR, Guthrie
380 DB, Hager M, Kuiper DL, Lockwood MA, Mitchell DG, Natchus MG, Sticher ZM,
381 Kolykhalov AA. 2019. The prophylactic and therapeutic activity of a broadly active
382 ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus
383 infection. *Antiviral Res* 171:104597.

- 384 10. Sheahan TP, Sims AC, Zhou S, Graham RL, Hill CS, Leist SR, Schäfer A, Dinnon KH,
385 Montgomery SA, Agostini ML, Pruijssers AJ, Chapell JD, Brown AJ, Bluemling GR,
386 Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ,
387 Swanstrom R, Denison MR, Baric RS. 2020. An orally bioavailable broad-spectrum antiviral
388 inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus. *Sci Transl Med*
389 12:eabb5883.
- 390 11. Toots M, Yoon J-J, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH,
391 Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL,
392 Natchus MG, Painter GR, Plemper RK. 2019. Characterization of orally efficacious
393 influenza drug with high resistance barrier in ferrets and human airway epithelia. *Sci Transl*
394 *Med* 11:eaax5866.
- 395 12. Tenforde MW. 2020. Characteristics of adult outpatients and inpatients with COVID-19 —
396 11 academic medical centers, United States, March–May 2020. *MMWR Morb Mortal Wkly*
397 *Rep* 69:841–846.
- 398 13. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L,
399 Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS, Edler C,
400 Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Puschel K, Aepfelbacher M, Huber
401 TB. 2020. Multiorgan and renal tropism of SARS-CoV-2. *N Engl J Med* 383:590–592.

402

403 **Figure Legends**

404 **Figure 1.** Arithmetic mean plasma concentrations of EIDD-1931 (50-1600 mg molnupiravir
405 single ascending doses).

406 **Figure 2.** Arithmetic mean plasma concentrations of EIDD-1931 (50-800 mg molnupiravir
407 twice-daily multiple ascending doses) on Day 1 (top) and Day 6 (bottom).

408 **Figure 3.** Arithmetic mean plasma concentration of EIDD-1931 (food effect).

Demographic		Single Dose 50-1600 mg Molnupiravir or Placebo (N = 64)	Multiple Dose 50-800 mg BID Molnupiravir or Placebo (N = 56)	Food Effect 200 mg Molnupiravir (N = 10)
Age (years)	Mean	39.6	36.5	45.3
	Range	21-60	19-60	30-60
Sex (n)	Male	53	49	7
	Female	11	7	3
Race (%)	White	95.3	92.9	90.0
	Black or African- American	4.7	1.8	---
	Other	---	5.4	10.0
Body Mass Index (kg/m²)	Mean	25.05	24.44	25.38
	Standard deviation	2.535	2.962	2.185

1 **Table 1.** Demography

2 Abbreviations: BID = twice daily; n = number of observations; N = number of subjects.

	Placebo (N = 16)	50 mg (N = 6)	100 mg (N = 6)	200 mg (N = 6)	400 mg (N = 6)	600 mg (N = 6)	800 mg (N = 6)	1200 mg (N = 6)	1600 mg (N = 6)
Overall (n, [nE])	7 [12]	2 [4]	---	3 [4]	3 [5]	4 [7]	2 [5]	1 [2]	2 [8]
Severity									
Mild (Grade 1)	7 [10]	2 [4]	---	3 [4]	3 [4]	4 [7]	2 [5]	1 [2]	2 [8]
Moderate (Grade 2)	1 [2]	---	---	---	1 [1]	---	---	---	---
Severe (Grade 3)	---	---	---	---	---	---	---	---	---
Related	2 [4]	1 [1]	---	2 [3]	---	1 [1]	---	---	---
Preferred Terms Reported By More Than 1 Subject (n)									
Headache	3	1	---	---	1	3	1	---	---
Catheter site pain*	1	---	---	---	1	1	---	---	---
Nausea	1	---	---	1	---	1	---	---	---
Rhinorrhoea	1	---	---	---	---	---	1	1	---
Back pain	---	---	---	---	---	1	1	---	---
Feeling hot	---	---	---	---	2	---	---	---	---
Pain in extremity	1	1	---	---	---	---	---	---	---

3 **Table 2.** Treatment-emergent adverse events (50-1600 mg molnupiravir single ascending doses)

4 Abbreviations: n = number of subjects with an adverse event; nE = number of adverse events; N

5 = number of subjects.

6 * venous cannula site pain

	Placebo BID (N = 14)	50 mg BID (N = 6)	100 mg BID (N = 6)	200 mg BID (N = 6)	300 mg BID (N = 6)	400 mg BID (N = 6)	600 mg BID (N = 6)	800 mg BID (N = 6)
Overall (n, [nE])	7 [11]	2 [2]	3 [3]	3 [9]	2 [3]	3 [5]	2 [2]	3 [5]
Severity								
Mild (Grade 1)	7 [11]	2 [2]	3 [3]	3 [6]	2 [3]	3 [5]	2 [2]	3 [5]
Moderate (Grade 2)	---	---	---	1 [3]	---	---	---	---
Severe (Grade 3)	---	---	---	---	---	---	---	---
Related	3 [4]	---	---	2 [3]	1 [1]	---	1 [1]	3 [4]
Preferred Terms Reported By More Than 1 Subject (n)								
Diarrhoea	1	---	---	1	---	---	1	1
Back pain	---	---	2	---	1	---	---	---
Headache	---	---	1	---	2	---	---	---
Somnolence	2	---	---	---	---	1	---	---

7 **Table 3.** Treatment-emergent adverse events (50-800 mg molnupiravir twice-daily multiple
8 ascending doses)
9 Abbreviations: BID = twice daily; n = number of subjects with an adverse event; nE = number of
10 adverse events; N = number of subjects.

Parameter	50 mg (N = 6)	100 mg (N = 6)	200 mg (N = 6)	400 mg (N = 6)	600 mg (N = 6)	800 mg (N = 6)	1200 mg (N = 6)	1600 mg (N = 6)
AUC_{last} (ng.h/mL)	415 (27.4)	917 (27.5)	1810 (20.0)	4000 (20.2)	6120 (21.6)	8720 (10.4)	13800 (11.7)	20700 (31.4)
AUC_{inf} (ng.h/mL)	432 (26.5)	932 (27.0)	1830 (19.6)	4010 (20.2)	6130 (21.4)	8740 (10.4)	13800 (11.8)	20700 (31.4)
C_{max} (ng/mL)	223 (46.2)	454 (42.2)	926 (12.6)	1850 (22.7)	2720 (27.0)	3640 (13.4)	4500 (17.9)	6350 (20.6)
t_{max} (h)	1.00 (0.517 – 1.00)	1.00 (0.500 – 1.50)	1.00 (0.500 – 1.00)	1.00 (0.500 – 1.00)	1.00 (1.00 – 1.00)	1.00 (0.500 – 1.00)	1.75 (1.00 – 2.50)	1.50 (1.00 – 2.00)
t_{1/2} (h)	0.945 (12.1)	0.907 (10.1)	1.02 (16.4)	1.03 (8.86)	1.06 (10.3)	1.29 (7.10)	1.81 (73.5)	4.59 (71.6)
Ae₀₋₂₄ (mg)	0.323 (53.6)	1.03 (68.1)	1.51 (86.2)	5.47 (108)	14.4 (47.7)	18.0 (14.7)	53.7 (41.4)	84.4 (29.9)
Fe₀₋₂₄ (%)	0.820 (53.6)	1.31 (68.1)	0.958 (86.2)	1.74 (108)	3.05 (47.7)	2.86 (14.7)	5.69 (41.4)	6.70 (29.9)

11 **Table 4.** Pharmacokinetic parameters of EIDD-1931 (50-1600 mg molnupiravir single ascending
12 doses)

13 Geometric means (percentage coefficient of variation) are presented, with the exception of t_{max}
14 where medians (minimum – maximum) are presented.

15 Abbreviations: Ae₀₋₂₄ = amount of the dose administered recovered in urine from time 0 to 24
16 hours postdose; AUC_{inf} = area under the plasma concentration-time curve from time 0
17 extrapolated to infinity; AUC_{last} = area under the plasma concentration-time curve from time 0 to
18 the last measurable non-zero concentration; C_{max} = maximum observed concentration;
19 Fe₀₋₂₄ = percentage of the dose administered recovered in urine from time 0 to 24 hours postdose;
20 N = number of subjects; t_{1/2} = apparent terminal elimination half-life; t_{max} = time of the
21 maximum observed concentration.

Parameter	n	Slope (90% Confidence Interval)	Between-subject Geometric Coefficient of Variation	Lack of Fit P-value
AUC _{inf} (ng.h/mL)	36	1.07 (1.02, 1.13)	21.5	0.9724
AUC _{last} (ng.h/mL)	36	1.09 (1.03, 1.15)	21.9	0.9750
C _{max} (ng/mL)	36	1.01 (0.927, 1.08)	29.8	0.9996

22 **Table 5.** Dose proportionality of EIDD-1931 (50-800 mg molnupiravir single ascending
23 doses) Abbreviations: AUC_{inf} = area under the plasma concentration-time curve from time 0
24 extrapolated to infinity; AUC_{last} = area under the plasma concentration-time curve from time 0 to
25 the last measurable non-zero concentration; C_{max} = maximum observed concentration; n =
26 number of observations.

Parameter	Day 1							Day 6						
	50 mg (N = 6)	100 mg (N = 6)	200 mg (N = 6)	300 mg (N = 6)	400 mg (N = 6)	600 mg (N = 6)	800 mg (N = 6)	50 mg (N = 6)	100 mg (N = 6)	200 mg (N = 6)	300 mg (N = 6)	400 mg (N = 6)	600 mg (N = 6)	800 mg (N = 5)
AUC_τ (ng.h/mL)	461 (15.7)	854 (19.8)	1660 (15.3)	3080 (17.3)	3800 (19.5)	6110 (26.9)	8190 (21.5)	432 (14.9)	968 (15.3)	1730 (25.2)	2960 (16.2)	3710 (21.6)	7110 (28.2)	8330 (17.9)
AUC_{last} (ng.h/mL)	444 (17.3)	835 (19.9)	1640 (15.5)	3080 (17.4)	3790 (19.5)	6110 (26.9)	8180 (21.5)	414 (16.2)	947 (15.7)	1720 (26.0)	2980 (16.3)	3730 (21.6)	7250 (28.1)	8450 (18.5)
AUC_{inf} (ng.h/mL)	461 (15.7)	855 (19.8)	1660 (15.3)	3090 (17.4)	3800 (19.5)	6680* (17.6)	8200 (21.6)	---	---	---	---	---	---	---
C_{max} (ng/mL)	223 (19.4)	395 (18.5)	766 (16.3)	1280 (15.2)	1530 (23.2)	2160 (31.4)	2770 (13.3)	188 (8.67)	434 (14.0)	742 (32.1)	1100 (20.6)	1470 (20.9)	2240 (20.9)	2970 (16.8)
t_{max} (h)	1.00 (1.00 – 1.00)	1.25 (1.00 – 2.03)	1.50 (1.00 – 1.50)	1.50 (1.00 – 1.50)	1.50 (1.00 – 2.00)	1.75 (1.00 – 6.00)	1.75 (1.50 – 2.50)	1.00 (1.00 – 1.50)	1.25 (1.00 – 1.50)	1.50 (0.500 – 1.50)	1.50 (1.00 – 2.00)	1.50 (1.00 – 1.50)	1.75 (1.50 – 2.50)	1.50 (1.00 – 2.02)
MR_{Cmax}	NC	NC	NC	NC	NC	329* (87.7)	512 (30.6)	NC	NC	NC	NC	NC	NC	413† (28.1)
t_{1/2} (h)	0.937 (14.0)	0.918 (9.08)	0.960 (10.4)	1.09 (17.7)	1.05 (13.1)	1.16* (3.50)	1.18 (7.28)	0.968 (15.5)	0.970 (15.8)	1.24 (36.4)	1.71 (47.1)	1.20* (9.58)	NC	7.08¶ (154)
RA_{AUCτ}	---	---	---	---	---	---	---	0.938 (7.80)	1.13 (9.25)	1.04 (18.0)	0.961 (14.7)	0.977 (11.7)	1.16 (12.2)	1.09 (11.8)
RA_{Cmax}	---	---	---	---	---	---	---	0.843 (16.0)	1.10 (11.4)	0.969 (23.8)	0.861 (14.3)	0.962 (18.5)	1.04 (20.0)	1.09 (7.15)
Ae₀₋₁₂ (mg)	0.391 (55.7)	0.993 (96.9)	1.38 (81.8)	3.37 (57.4)	4.57 (57.0)	11.9 (22.9)	22.7 (34.4)	0.336 (64.5)	0.915 (48.0)	1.76 (85.5)	3.14 (63.4)	5.32 (47.5)	16.4 (39.9)	18.9 (81.6)
Fe₀₋₁₂ (%)	0.993 (55.7)	1.26 (96.9)	0.879 (81.8)	1.43 (57.4)	1.45 (57.0)	2.52 (22.9)	3.61 (34.4)	0.854 (64.5)	1.16 (48.0)	1.12 (85.5)	1.33 (63.4)	1.69 (47.5)	3.48 (39.9)	3.00 (81.6)

27 **Table 6.** Pharmacokinetic parameters of EIDD-1931 (50-800 mg molnupiravir twice-daily multiple ascending doses)

28 Geometric means (percentage coefficient of variation) are presented, with the exception of t_{\max} where medians (minimum –
29 maximum) are presented.

30 * N=5; † N=3 ¶ N=4.

31 Abbreviations: Ae_{0-12} = amount of dose administered recovered in urine from time 0 to 12 hours postdose; AUC_{τ} = area under the
32 plasma concentration-time curve during a dosing interval; AUC_{inf} = area under the plasma concentration-time curve from time 0
33 extrapolated to infinity; AUC_{last} = area under the plasma concentration-time curve from time 0 to the last measurable non-zero
34 concentration; C_{\max} = maximum observed concentration; Fe_{0-12} = percentage of the dose administered recovered in urine from time 0
35 to 12 hours postdose; MR = metabolite ratio; N = number of subjects; NC = not calculated; RA = accumulation ratio; $t_{1/2}$ = apparent
36 terminal elimination half-life; t_{\max} = time of the maximum observed concentration.

Parameter	Day 1				Day 6			
	n	Slope (90% Confidence Interval)	Between-subject Geometric Coefficient of Variation	Lack of Fit P-value	n	Slope (90% Confidence Interval)	Between-subject Geometric Coefficient of Variation	Lack of Fit P-value
AUC _{inf} (ng.h/mL)	53	1.10 (1.06, 1.14)	19.6	0.3149	---	---	---	---
AUC _{last} (ng.h/mL)	54	1.11 (1.07, 1.15)	20.8	0.4483	---	---	---	---
AUC _τ (ng.h/mL)	---	---	---	---	41	1.08 (1.02, 1.14)	20.5	0.3670
C _{max} (ng/mL)	54	0.957 (0.916, 0.998)	20.1	0.7011	41	0.971 (0.915, 1.03)	20.3	0.7798

37 **Table 7.** Dose proportionality of EIDD-1931 (50-1600 mg molnupiravir single ascending doses
38 [Day 1] and 50-800 mg molnupiravir twice-daily multiple ascending doses [Day
39 6]) Abbreviations: AUC_τ = area under the plasma concentration-time curve during a dosing
40 interval; AUC_{inf} = area under the plasma concentration-time curve from time 0 extrapolated to
41 infinity; AUC_{last} = area under the plasma concentration-time curve from time 0 to the last
42 measurable non-zero concentration; C_{max} = maximum observed concentration; n = number of
43 observations.


Parameter	200 mg Fasted (N = 10)	200 mg Fed (N = 10)
AUC_{last} (ng.h/mL)	1950 (29.9)	1870 (29.0)
AUC_{inf} (ng.h/mL)	1980 (29.3)	1890 (28.8)
C_{max} (ng/mL)	893 (36.8)	575 (27.7)
t_{max} (h)	1.00 (1.00 – 2.50)	3.00 (2.00-4.00)
t_{1/2} (h)	0.977 (13.0)	1.09 (16.3)
FE_{AUCinf}	---	0.955 (9.7)
FE_{Cmax}	---	0.644 (22.5)
Ae₀₋₂₄ (mg)	1.76 (45.6)	1.63 (54.2)
Fe₀₋₂₄ (%)	1.12 (45.6)	1.04 (54.2)

44 **Table 8.** Pharmacokinetic parameters of EIDD-1931 (food effect)

45 Geometric means (percentage coefficient of variation) are presented, with the exception of t_{max}
46 where medians (minimum – maximum) are presented.

47 Abbreviations: Ae₀₋₂₄ = amount of the dose administered recovered in urine from time 0 to 24
48 hours postdose; AUC_{inf} = area under the plasma concentration-time curve from time 0
49 extrapolated to infinity; AUC_{last} = area under the plasma concentration-time curve from time 0 to
50 the last measurable non-zero concentration; C_{max} = maximum observed concentration; Fe<sub>0-
51 24</sub> = percentage of the dose administered recovered in urine from time 0 to 24 hours postdose;
52 FE_{AUCinf} = ratio of area under the plasma concentration-time curve from time 0 extrapolated to
53 infinity (fed:fasted); FE_{Cmax} = ratio of maximum observed concentration (fed:fasted);
54 t_{1/2} = apparent terminal elimination half-life; t_{max} = time of the maximum observed concentration.


1 **Figure 1.**




— 50 mg molnupiravir PIB (fasted) — 100 mg molnupiravir PIB (fasted)
— 200 mg molnupiravir PIB (fasted) — 400 mg molnupiravir PIB (fasted)
— 600 mg molnupiravir PIB (fasted) — 800 mg molnupiravir PIB (fasted)
— 1200 mg molnupiravir capsule (fasted) — 1600 mg molnupiravir capsule (fasted)

2

3 **Figure 2.**




4



5

6 **Figure 3.**



7